Table 3.
In vivo Anti-Inflammatory Activities of Compounds IIIa–i
| Compound No. | Anti-Inflammatory Activity % (AI)a | ||
|---|---|---|---|
| 1 h | 3 h | 5 h | |
| IIIa | 0.95 ± 0.10* (34%) | 0.83 ± 0.12* (41%) | 0.85 ± 0.06*(39%) |
| IIIb | 1.00 ± 0.11* (31%) | 0.95 ± 0.12 (32%) | 0.90 ± 0.14 (36%) |
| IIIc | 1.10 ± 0.08 (24%) | 1.00 ± 0.10 (29%) | 0.65 ± 0.05*** (54%) |
| IIId | 1.05 ± 0.10 (28%) | 0.95 ± 0.12 (32%) | 1.05 ± 0.13 (55%) |
| IIIe | 1.05 ± 0.12 (28%) | 0.95 ± 0.09 (32%) | 0.78 ± 0.08** (45%) |
| IIIf | 0.60 ± 0.12***(52%) | 0.58 ± 0.11***(59%) | 0.48 ± 0.14*** (66%) |
| IIIg | 1.08 ± 0.09 (26%) | 0.65 ± 0.13***(54%) | 0.60 ± 0.15*** (57%) |
| IIIh | 0.49 ± 0.05***(67%) | 0.58 ± 0.11***(63%) | 0.58 ± 0.17***(57%) |
| IIIi | 1.10 ± 0.14 (24%) | 0.80 ± 0.15**(43%) | 0.68 ± 0.13** (52%) |
| Control | 1.45 ± 0.15 (0%) | 1.58 ± 0.15 (0%) | 1.33 ± 0.10 (0%) |
| Celecoxib | 0.83 ± 0.09**(43%) | 0.80 ± 0.11** (43%) | 0.65 ± 0.10*** (54%) |
Notes: aThe presented values are the average of triplicate experiments ± SEM, Significance levels *p ˂ 0.05, **p ˂ 0.01 and ***p ˂ 0.001 as compared to the control group.